Extended Treatment with Glial Cell Line-Derived Neurotrophic Factor in Parkinson's Disease.

Autor: Whone, Alan L., Boca, Mihaela, Luz, Matthias, Woolley, Max, Mooney, Lucy, Dharia, Sonali, Broadfoot, Jack, Cronin, David, Schroers, Christian, Barua, Neil U., Longpre, Lara, Barclay, C. Lynn, Boiko, Chris, Johnson, Greg A., Fibiger, H. Christian, Harrison, Rob, Lewis, Owen, Pritchard, Gemma, Howell, Mike, Irving, Charlie

Publikováno v: Journal of Parkinson's Disease; 2019, Vol. 9 Issue 2, p301-313, 13p

Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson's disease.

Autor: Whone A; Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.; Neurological and Musculoskeletal Sciences Division, North Bristol NHS Trust, Bristol, UK., Luz M; MedGenesis Therapeutix Inc., Victoria, BC, Canada., Boca M; Neurological and Musculoskeletal Sciences Division, North Bristol NHS Trust, Bristol, UK., Woolley M; Renishaw plc, New Mills, Wotton-under-Edge, Gloucestershire, UK., Mooney L; Neurological and Musculoskeletal Sciences Division, North Bristol NHS Trust, Bristol, UK., Dharia S; Neurological and Musculoskeletal Sciences Division, North Bristol NHS Trust, Bristol, UK., Broadfoot J; Neurological and Musculoskeletal Sciences Division, North Bristol NHS Trust, Bristol, UK., Cronin D; Neurological and Musculoskeletal Sciences Division, North Bristol NHS Trust, Bristol, UK., Schroers C; Neurological and Musculoskeletal Sciences Division, North Bristol NHS Trust, Bristol, UK., Barua NU; Neurological and Musculoskeletal Sciences Division, North Bristol NHS Trust, Bristol, UK., Longpre L; MedGenesis Therapeutix Inc., Victoria, BC, Canada., Barclay CL; MedGenesis Therapeutix Inc., Victoria, BC, Canada., Boiko C; MedGenesis Therapeutix Inc., Victoria, BC, Canada., Johnson GA; MedGenesis Therapeutix Inc., Victoria, BC, Canada., Fibiger HC; MedGenesis Therapeutix Inc., Victoria, BC, Canada., Harrison R; Renishaw plc, New Mills, Wotton-under-Edge, Gloucestershire, UK., Lewis O; Renishaw plc, New Mills, Wotton-under-Edge, Gloucestershire, UK., Pritchard G; Renishaw plc, New Mills, Wotton-under-Edge, Gloucestershire, UK., Howell M; Renishaw plc, New Mills, Wotton-under-Edge, Gloucestershire, UK., Irving C; Renishaw plc, New Mills, Wotton-under-Edge, Gloucestershire, UK., Johnson D; Renishaw plc, New Mills, Wotton-under-Edge, Gloucestershire, UK., Kinch S; Renishaw plc, New Mills, Wotton-under-Edge, Gloucestershire, UK., Marshall C; The Wales Research and Diagnostic Positron Emission Tomography Imaging Centre (PETIC), Cardiff University, Cardiff, UK., Lawrence AD; School of Psychology, Cardiff University, Cardiff, UK., Blinder S; Department of Physics and Astronomy, The University of British Columbia, Vancouver, BC, Canada., Sossi V; Department of Physics and Astronomy, The University of British Columbia, Vancouver, BC, Canada., Stoessl AJ; Djavad Mowafaghian Centre for Brain Health, Faculty of Medicine, The University of British Columbia, Vancouver, BC, Canada., Skinner P; Renishaw plc, New Mills, Wotton-under-Edge, Gloucestershire, UK., Mohr E; MedGenesis Therapeutix Inc., Victoria, BC, Canada., Gill SS; Neurological and Musculoskeletal Sciences Division, North Bristol NHS Trust, Bristol, UK.; Renishaw plc, New Mills, Wotton-under-Edge, Gloucestershire, UK.

Publikováno v: Brain : a journal of neurology [Brain] 2019 Mar 01; Vol. 142 (3), pp. 512-525.